Suomi - suomi - Fimea (Suomen lääkevirasto)

a. vogel oy - hyperici yrtti, tuore ote henki kuiva,koko hypericini - tabletti - hyperici herba

Suomi - suomi - Fimea (Suomen lääkevirasto)

photonamic gmbh & co. kg - 5-aminolevuliinihappo-hydrokloridi - lääkelaastari - 8 mg - aminolevuliinihappo

Euroopan unioni - suomi - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karsinooma, ei-pienisoluinen keuhko - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinibi (fosfaatteina) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiset aineet - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polysytemia vera (pv)jakavi on tarkoitettu aikuisille potilaille, joilla on polysytemia vera, jotka ovat resistenttejä tai intolerantteja ja hydroksiurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

eisai gmbh - bexaroteenin - lymfooma, t-solu, iho - antineoplastiset aineet - targretin-kapselit on tarkoitettu hoidettaessa kehittyneitä vaiheita ihon t-solulymfooma (ctcl) -potilaita, jotka ovat tulenkestäviä ainakin yhdelle systeemiselle hoidolle.

Suomi - suomi - Fimea (Suomen lääkevirasto)

abcur ab - methadoni hydrochloridum - tabletti - 5 mg - metadoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

abcur ab - methadoni hydrochloridum - tabletti - 20 mg - metadoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

abcur ab - methadoni hydrochloridum - tabletti - 10 mg - metadoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

abcur ab - methadoni hydrochloridum - tabletti - 40 mg - metadoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

abcur ab - methadone hydrochloride - tabletti - 5 mg - metadoni